Trials in 2

1-3 of 3

• 

  RestartResume

  INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)

  RestartResume

  INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)

  Movement Disorders

  INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)

  Jerrold L. Vitek, MD, PhD

  Jerrold L. Vitek, MD, PhD

• 

  RestartResume

  RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)

  RestartResume

  RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)

  Neuro-oncology

  RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)

  Christopher Moertel, MD

  Christopher Moertel, MD

• 

  RestartResume

  ELEVATE (Qulipta for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments; NCT04740827)

  RestartResume

  ELEVATE (Qulipta for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments; NCT04740827)

  Headache & Pain

  ELEVATE (Qulipta for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments; NCT04740827)

  Patricia Pozo-Rosich, MD, PhD

  Patricia Pozo-Rosich, MD, PhD